1-methyl-2-[(phenylthio)methyl]-3-indolecarbonitrile

1-methyl-2-[(phenylthio)methyl]-3-indolecarbonitrile, also known as **MK-801**, is a **non-competitive NMDA receptor antagonist**.

Here's why it's important for research:

**1. NMDA Receptor Studies:**

* **Understanding Neuronal Function:** NMDA receptors are critical for learning, memory, and synaptic plasticity in the brain. MK-801 blocks these receptors, allowing researchers to study their role in various neurological processes.
* **Investigating Neurological Disorders:** MK-801 has been used to model conditions like schizophrenia and Alzheimer's disease. By mimicking their effects on NMDA receptors, it helps researchers understand the underlying mechanisms of these disorders.
* **Developing New Drugs:** Research on MK-801 has led to the development of other NMDA receptor antagonists that are being investigated for their potential therapeutic effects in conditions like chronic pain and stroke.

**2. Pharmacology and Toxicology Research:**

* **Drug Interaction Studies:** Understanding how MK-801 interacts with other drugs is crucial for predicting potential side effects and drug interactions.
* **Toxicity Studies:** MK-801 can have significant adverse effects, including neurotoxicity. Research on its toxic mechanisms helps develop safer and more effective drug candidates.

**3. Basic Research:**

* **Cell Signaling Pathways:** MK-801 has been used to study the complex signaling pathways involved in NMDA receptor activation and downstream effects.
* **Neuroprotective Effects:** Some studies suggest that MK-801 might have neuroprotective effects in certain situations, but further research is needed.

**Important Note:** MK-801 is a potent drug with serious side effects. It is only used in controlled research settings, not for therapeutic purposes in humans.

In summary, 1-methyl-2-[(phenylthio)methyl]-3-indolecarbonitrile (MK-801) is a crucial research tool that has contributed significantly to our understanding of NMDA receptors, their role in neurological processes, and the development of new drugs.